Dana-Farber Privacy Statement
Your privacy is important to us, so we operate the site by the following principles:
You may use our site without disclosing personally identifiable information. We want to be clear that we will not obtain such information about you unless you choose to submit it to us. If you supply personally identifiable information (such as name, address or telephone numbers) for various purposes on this site, we only use the information for that purpose (such as to provide the service or information you have requested).
Dana-Farber takes every precaution to protect our users' information. When a registration/order form asks users to enter sensitive information (such as credit card number and/or diagnosis), that information is encrypted and is protected with the best encryption software in the industry-SSL.
Should you electronically request a referral to a Dana-Farber physician, we will use the information you submit to arrange for care where appropriate. While we use SSL encryption to protect sensitive information online, we also do everything in our power to protect user-information off line. Our software and hardware is configured to provide maximum security.
Information Collection and Use
Dana-Farber is the sole owner of the personal medical information collected on this site. We will not sell, share, or rent this information to others. Dana-Farber occasionally trades its contributor mailing lists with other non-profit organizations. This process saves us money and is carefully monitored and one may always opt out.
In the News
Dr. P. Janne and Dr. C. Paweletz discuss an innovative approach for tumor genotyping and disease monitoring for targeted lung cancer therapies.
Belfer & Janssen announce collaboration on cancer immunotherapies for lung cancer
Phase I Study of Novel Third-Generation EGFR Inhibitor Holds Promise Against Resistance Mutation in Patients With Non–Small Cell Lung Cancer
Belfer scientists identified phospho-IRF3 as a biomarker of TBK1 activity in K-Ras mutant pancreatic cancer. TBK1 inhibition may have therapeutic potential in defined patient populations.
Poster presentation, PDx Platform of High Grade Serous Ovarian Cancer, at the 2014 AACR General Meeting in San Diego by Sangeetha Palakurthi PhD, Head of Cancer Biology and Pharmacology.